Mark O. Palmier

1.1k total citations
25 papers, 892 citations indexed

About

Mark O. Palmier is a scholar working on Molecular Biology, Cancer Research and Hematology. According to data from OpenAlex, Mark O. Palmier has authored 25 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Cancer Research and 7 papers in Hematology. Recurrent topics in Mark O. Palmier's work include Protease and Inhibitor Mechanisms (9 papers), Peptidase Inhibition and Analysis (5 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). Mark O. Palmier is often cited by papers focused on Protease and Inhibitor Mechanisms (9 papers), Peptidase Inhibition and Analysis (5 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). Mark O. Palmier collaborates with scholars based in United States and Italy. Mark O. Palmier's co-authors include Steven R. Van Doren, Tze-Chein Wun, GJ Jr Broze, WF Novotny, JP Miletich, Christine E. Smith, Ned R. Siegel, Kathleen C. Day, R. Bhaskaran and Dana R. Abendschein and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Mark O. Palmier

25 papers receiving 863 citations

Peers

Countries citing papers authored by Mark O. Palmier

Since Specialization

Citations

This map shows the geographic impact of Mark O. Palmier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark O. Palmier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark O. Palmier more than expected).

Fields of papers citing papers by Mark O. Palmier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark O. Palmier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark O. Palmier. The network helps show where Mark O. Palmier may publish in the future.

Co-authorship network of co-authors of Mark O. Palmier

This figure shows the co-authorship network connecting the top 25 collaborators of Mark O. Palmier. A scholar is included among the top collaborators of Mark O. Palmier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark O. Palmier. Mark O. Palmier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Apparent Tradeoff of Higher Activity in MMP-12 for Enhanced Stability and Flexibility in MMP-3 2010 ·Biophysical Journal ·Xiangyang Liang, (unknown), (unknown), R. Bhaskaran, (unknown), (unknown), (unknown), Mark O. Palmier, Steven R. Van Doren	13
2	NMR and Bioinformatics Discovery of Exosites That Tune Metalloelastase Specificity for Solubilized Elastin and Collagen Triple Helices 2010 ·Journal of Biological Chemistry ·Mark O. Palmier, Yan G. Fulcher, R. Bhaskaran, (unknown), Gregg B. Fields, Steven R. Van Doren	20
3	Solubilized elastin substrate for continuous fluorimetric assay of kinetics of elastases 2010 ·Analytical Biochemistry ·Mark O. Palmier, Yan G. Fulcher, Steven R. Van Doren	6
4	An examination of the proteolytic activity for bovine pregnancy-associated glycoproteins 2 and 12 2009 ·Biological Chemistry ·Bhanu P. Telugu, Mark O. Palmier, Steven R. Van Doren, Jonathan A. Green	26
5	MMP-12 Catalytic Domain Recognizes Triple Helical Peptide Models of Collagen V with Exosites and High Activity 2008 ·Journal of Biological Chemistry ·R. Bhaskaran, Mark O. Palmier, Janelle L. Lauer‐Fields, Gregg Fields, Steven R. Van Doren	37
6	Inactivation of N‐TIMP‐1 by N‐terminal acetylation when expressed in bacteria 2008 ·Biopolymers ·Steven R. Van Doren, Shuo Wei, Guanghua Gao, Beverly B. DaGue, Mark O. Palmier, Harinath Bahudhanapati, Keith Brew	15
7	Rapid determination of enzyme kinetics from fluorescence: Overcoming the inner filter effect 2007 ·Analytical Biochemistry ·Mark O. Palmier, Steven R. Van Doren	103
8	Solution Structure of Inhibitor-Free Human Metalloelastase (MMP-12) Indicates an Internal Conformational Adjustment 2007 ·Journal of Molecular Biology ·R. Bhaskaran, Mark O. Palmier, Nusayba A. Bagegni, Xiangyang Liang, Steven R. Van Doren	18
9	Three-dimensional structure of human cytomegalovirus protease 1996 ·Nature ·Huey‐Sheng Shieh, Ravi G. Kurumbail, Anna M. Stevens, Roderick A. Stegeman, (unknown), (unknown), Arthur J. Wittwer, Mark O. Palmier, Roger C. Wiegand, Barry C. Holwerda, William C. Stallings	119
10	Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. coli 1994 ·Protein Expression and Purification ·Mark E. Gustafson, Katrin Junger, Tze-Chein Wun, (unknown), (unknown), D. Welsch, Mark G. Obukowicz, (unknown), Gary S. Bild, Richard M. Leimgruber, Mark O. Palmier, (unknown), (unknown), Ronald B. Frazier, Gerald R. Galluppi, (unknown)	11
11	Refold and Characterization of Recombinant Tissue Factor Pathway Inhibitor Expressed in Escherichia coli 1994 ·Thrombosis and Haemostasis ·(unknown), Mark O. Palmier, K K Kretzmer, (unknown), Rodney G. Combs, Mark G. Obukowicz, Ronald B. Frazier, Gary S. Bild, (unknown), (unknown), Kevin L. Duffin, Mark E. Gustafson, (unknown), (unknown), Gerald R. Galluppi, Tze-Chein Wun	43
12	Clearance of Recombinant Tissue Factor Pathway Inhibitor (TFPI) in Rabbits 1992 ·Thrombosis and Haemostasis ·Mark O. Palmier, (unknown), (unknown), (unknown), Alan Wilson, Tze-Chein Wun	46
13	Molecular cloning of the gene encoding the bovine brain ribonucelase and its expression in different regions of the brain 1991 ·Nucleic Acids Research ·Maurizio Sasso, Antonella Carsana, (unknown), Cristina Cosi, Salvatore Sorrentino, (unknown), Mark O. Palmier, Edda Russo, Adriana Furia	41
14	Purification and properties of heparin-releasable lipoprotein- associated coagulation inhibitor 1991 ·Blood ·WF Novotny, Mark O. Palmier, (unknown), GJ Jr Broze, JP Miletich	13
15	Crystallization of a chymotrypsin inhibitor from Erythrina caffra seeds 1990 ·Journal of Molecular Biology ·Huey‐Sheng Shieh, (unknown), Mark O. Palmier, Tze-Chein Wun, Richard M. Leimgruber, Sherin S. Abdel‐Meguid	2
16	Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase 1989 ·Journal of Biological Chemistry ·Tze-Chein Wun, Mark O. Palmier, Ned R. Siegel, Christine E. Smith	80
17	Renal reduced nicotinamide adenine dinucleotide phosphate:cytochrome c reductase-mediated metabolism of the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide. 1985 ·PubMed ·Michael B. Mattammal, Terry V. Zenser, Mark O. Palmier, Bernard B. Davis	7
18	Metabolic activation of the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide by prostaglandin H synthase 1984 ·Carcinogenesis ·Terry V. Zenser, Mark O. Palmier, Michael B. Mattammal, Bernard B. Davis	10
19	Comparative effects of prostaglandin H synthase-catalyzed binding of two 5-nitrofuran urinary bladder carcinogens. 1983 ·Journal of Pharmacology and Experimental Therapeutics ·Terry V. Zenser, Mark O. Palmier, Michael B. Mattammal, Robert I. Bolla, Bernard B. Davis	11
20	Microsomal nitroreductase activity of rabbit kidney and bladder: implications in 5-nitrofuran-induced toxicity. 1981 ·Journal of Pharmacology and Experimental Therapeutics ·Terry V. Zenser, Michael B. Mattammal, Mark O. Palmier, Bernard B. Davis	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact